GtoPdb Ligand ID: 9801

Synonyms: CA170_01519.g57 IgG4P | UCB-7665 | UCB7665
Compound class: Antibody
Comment: Rozanolixizumab is an anti-human FcRn monoclonal antibody that is being developed for potential use in the treatment of IgG-driven autoimmune diseases [1-2].
1. Finney HM, Lawson ADG, Shaw SG, Smith BJ, Tyson KL, Kevorkian L. (2014)
Anti-fcrn antibodies.
Patent number: WO2014019727. Assignee: Ucb Pharma S.A.. Priority date: 14/05/2012. Publication date: 06/02/2014.
2. Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, Christodoulou L, Jones E, Price G, Smith B et al.. (2017)
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
Sci Transl Med, 9 (414). [PMID:29093180]